Discontinuation of Preventive Medicines in Older People with Limited Life Expectancy: A Systematic Review
- 323 Downloads
In the presence of multimorbidity and limited life expectancy (LLE), the need for continued use of preventive medicines becomes uncertain as they may neither improve health nor confer continued health benefits.
Our objective was to systematically review the literature to examine the discontinuation of preventive medicines in older people with LLE.
A systematic literature search was conducted using the Ovid MEDLINE, Embase, Cumulative Index to Nursing and Allied Health Literature, and the Cochrane Central Register databases. Studies investigating discontinuation of preventive medicines in older individuals (mean age ≥65 years) with LLE (≤12 months) published between 1 January 1997 and 28 February 2017 were included. The Cochrane risk-of-bias assessment criteria and the Newcastle–Ottawa Scale were used to assess the quality of the studies.
Ten studies—a randomized controlled trial (RCT), two case–control studies, and seven cohort studies—involving 26,854 participants with a mean age ranging from 66.0 to 85.0 years were included in this review. The studies were primarily conducted in palliative care (n = 3), residential facility (n = 2), and community (n = 1) settings, and the remainder were pharmacoepidemiological studies (n = 4). The most common life-limiting illnesses were cancer (n = 5), followed by other unspecified illnesses (n = 4) and advanced dementia (n = 1). The most common preventive medicine discontinued was statins, followed by warfarin and aspirin. LLE potentially prompted discontinuation; however, some individuals continued to receive preventive medicines until they died.
The review found that withdrawal of preventive medicines at the end of life is challenging. Decisions about the discontinuation of preventive medicines for individuals approaching the end of life are increasingly complicated by the lack of clear deprescribing guidelines for these medicines.
Compliance with Ethical Standards
The authors thank the RiPE (Research in Pharmacoepidemiology) group, School of Pharmacy, University of Otago, New Zealand, for providing support. Sujita Narayan is supported by a doctoral scholarship from the School of Pharmacy, University of Otago, Dunedin, New Zealand. The funding institution did not play a role in the study concept, data analysis, or interpretation.
Conflicts of interest
Sujita Narayan and Prasad Nishtala have no conflicts of interest relevant to the content of this review.
All patient data evaluated in this review were de-identified.
- 2.McNeil MJ, Kamal AH, Kutner JS, Ritchie CS, Abernethy AP. The Burden of polypharmacy in patients near the end of life. J Pain Symptom Manage. 2016;51(2):178–83.e2.Google Scholar
- 4.Narayan SW, Nishtala PS. Associations of potentially inappropriate medicine use with fall-related hospitalisations and primary care visits in older New Zealanders: a population-level study using the updated 2012 Beers Criteria. Drugs Real World Outcomes. 2015;2(2):137–41.CrossRefPubMedPubMedCentralGoogle Scholar
- 19.The New Zealand Formulary. http://nzformulary.org/. Accessed 22 July 2016.
- 20.The Cochrane Collaboration’s tool for assessing risk of bias. London: Cochrane Collaboration. http://handbook.cochrane.org/chapter_8/8_5_the_cochrane_collaborations_tool_for_assessing_risk_of_bias.htm. Accessed 24 Mar 2017.
- 21.The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 24 Mar 2017.
- 22.STROBE Statement. https://www.strobe-statement.org/index.php?id=strobe-home. Accessed 24 Mar 2017.
- 33.Poudel A, Yates P, Rowett D, Nissen LM. Use of preventive medication in patients with limited life expectancy: a systematic review. J Pain Symptom Manage. 2017;53(6):1097–1110.e1. doi: 10.1016/j.jpainsymman.2016.12.350 (Epub 2017 Feb 9).